Identification of an antibody‐based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues

por Finger, Joshua N., Brusq, Jean‐Marie, Campobasso, Nino, Cook, Michael N., Deutsch, Jennifer, Haag, Heather, Harris, Philip A., Jenkins, Earl L., Joglekar, Devika, Lich, John D., Maguire, Sean, Nagilla, Rakesh, Rivera, Elizabeth J., Sun, Helen, Votta, Bartholomew J., Bertin, John, Gough, Peter J.
Publicado 2017

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

por Weisel, Kathleen, Scott, Nicola E., Tompson, Debra J., Votta, Bartholomew J., Madhavan, Sujith, Povey, Kat, Wolstenholme, Allen, Simeoni, Monica, Rudo, Todd, Richards‐Peterson, Lauren, Sahota, Tarjinder, Wang, J. Gene, Lich, John, Finger, Joshua, Verticelli, Adeline, Reilly, Michael, Gough, Peter J., Harris, Philip A., Bertin, John, Wang, Mei‐Lun
Publicado 2017

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

por Mares, Alina, Miah, Afjal H., Smith, Ian E. D., Rackham, Mark, Thawani, Aditya R., Cryan, Jenni, Haile, Pamela A., Votta, Bartholomew J., Beal, Allison M., Capriotti, Carol, Reilly, Michael A., Fisher, Don T., Zinn, Nico, Bantscheff, Marcus, MacDonald, Thomas T., Vossenkamper, Anna, Dace, Phoebe, Churcher, Ian, Benowitz, Andrew B., Watt, Gillian, Denyer, Jane, Scott-Stevens, Paul, Harling, John D.
Publicado 2020